Please use this identifier to cite or link to this item:
https://doi.org/10.1177/1747493016676615
DC Field | Value | |
---|---|---|
dc.title | Durability of the beneficial effect of MLC601 (NeuroAiD™) on functional recovery among stroke patients from the Philippines in the CHIMES and CHIMES-E studies | |
dc.contributor.author | Navarro, J.C | |
dc.contributor.author | Chen, C.L.H | |
dc.contributor.author | Lee, C.F | |
dc.date.accessioned | 2020-10-23T04:49:53Z | |
dc.date.available | 2020-10-23T04:49:53Z | |
dc.date.issued | 2017 | |
dc.identifier.citation | Navarro, J.C, Chen, C.L.H, Lee, C.F (2017). Durability of the beneficial effect of MLC601 (NeuroAiD™) on functional recovery among stroke patients from the Philippines in the CHIMES and CHIMES-E studies. International Journal of Stroke 12 (3) : 285-291. ScholarBank@NUS Repository. https://doi.org/10.1177/1747493016676615 | |
dc.identifier.issn | 17474930 | |
dc.identifier.uri | https://scholarbank.nus.edu.sg/handle/10635/179514 | |
dc.description.abstract | Background and Aim: A pre-specified country analysis of subjects from the Philippines in the CHInese Medicine NeuroAiD Efficacy on Stroke recovery (CHIMES) Study showed significantly improved functional and neurological outcomes on MLC601 at month (M) 3. We aimed to assess these effects on long-term functional recovery in the Filipino cohort. Methods: The CHIMES-E (extension) Study evaluated subjects who completed three months of randomized placebo-controlled treatment in CHIMES up to two years. Blinding of treatment allocation was maintained and all subjects received standard stroke care and rehabilitation. Modified Rankin Score (mRS) and Barthel Index (BI) were assessed in-person at M3 and by telephone at M6, M12, M18, M24. Odds ratios (OR) with corresponding 95% confidence intervals (CI) for functional recovery using ordinal analysis of mRS and for achieving functional independence (mRS 0-1 or BI ≥ 95) at each time point were calculated, adjusting for age, sex, baseline National Institute of Health Stroke Scale (NIHSS), onset-to-treatment time (OTT) and pre-stroke mRS. Results: The 378 subjects (MLC601 192, placebo 186) included in CHIMES-E from the Philippines (mean age 60.2 ± 11.1) had more women (p < 0.001), worse baseline NIHSS (p < 0.001) and longer onset to treatment time (p = 0.002) compared to other countries. Baseline characteristics were similar between treatment groups. The treatment effect of MLC601 seen at M3 peaked at M6 with OR for mRS shift of 1.53 (95% CI 1.05–2.22), mRS dichotomy 0–1 of 1.77 (95% CI 1.10–2.83), and BI ≥ 95 of 1.87 (95% CI 1.16–3.02). The beneficial effect persisted up to M24. Conclusion: The beneficial effect of MLC601 seen at M3 in the Filipino cohort is durable up to two years after stroke. © 2016, © 2016 World Stroke Organization. | |
dc.rights | Attribution 4.0 International | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.source | Unpaywall 20201031 | |
dc.subject | mlc 601 | |
dc.subject | neuroprotective agent | |
dc.subject | unclassified drug | |
dc.subject | herbaceous agent | |
dc.subject | Neuroaid | |
dc.subject | neuroprotective agent | |
dc.subject | acute coronary syndrome | |
dc.subject | adult | |
dc.subject | Article | |
dc.subject | Barthel index | |
dc.subject | cerebrovascular accident | |
dc.subject | cohort analysis | |
dc.subject | controlled study | |
dc.subject | diabetes mellitus | |
dc.subject | diarrhea | |
dc.subject | female | |
dc.subject | Filipino (people) | |
dc.subject | follow up | |
dc.subject | gastritis | |
dc.subject | human | |
dc.subject | hypertension | |
dc.subject | kidney disease | |
dc.subject | long term care | |
dc.subject | major clinical study | |
dc.subject | male | |
dc.subject | National Institutes of Health Stroke Scale | |
dc.subject | Philippines | |
dc.subject | pneumonia | |
dc.subject | Rankin scale | |
dc.subject | rheumatic disease | |
dc.subject | stroke patient | |
dc.subject | time to treatment | |
dc.subject | transient ischemic attack | |
dc.subject | Chinese medicine | |
dc.subject | convalescence | |
dc.subject | drug effects | |
dc.subject | interview | |
dc.subject | middle aged | |
dc.subject | odds ratio | |
dc.subject | randomized controlled trial | |
dc.subject | severity of illness index | |
dc.subject | Stroke | |
dc.subject | stroke rehabilitation | |
dc.subject | time factor | |
dc.subject | treatment outcome | |
dc.subject | Drugs, Chinese Herbal | |
dc.subject | Female | |
dc.subject | Follow-Up Studies | |
dc.subject | Humans | |
dc.subject | Interviews as Topic | |
dc.subject | Male | |
dc.subject | Medicine, Chinese Traditional | |
dc.subject | Middle Aged | |
dc.subject | Neuroprotective Agents | |
dc.subject | Odds Ratio | |
dc.subject | Philippines | |
dc.subject | Recovery of Function | |
dc.subject | Severity of Illness Index | |
dc.subject | Stroke | |
dc.subject | Stroke Rehabilitation | |
dc.subject | Time Factors | |
dc.subject | Time-to-Treatment | |
dc.subject | Treatment Outcome | |
dc.type | Article | |
dc.contributor.department | MEDICINE | |
dc.contributor.department | PHARMACOLOGY | |
dc.contributor.department | DUKE-NUS MEDICAL SCHOOL | |
dc.description.doi | 10.1177/1747493016676615 | |
dc.description.sourcetitle | International Journal of Stroke | |
dc.description.volume | 12 | |
dc.description.issue | 3 | |
dc.description.page | 285-291 | |
dc.published.state | Published | |
Appears in Collections: | Elements Staff Publications |
Show simple item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
10_1177_1747493016676615.pdf | 2.58 MB | Adobe PDF | OPEN | None | View/Download |
This item is licensed under a Creative Commons License